One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk

(MedPage Today) — Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort study suggested…